Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in the Bioscience Industry to Its Board of Directors
The Fitzsimons Redevelopment Authority (FRA) is adding four of the area's most well-known and successful leaders in the Bioscience Industry to its Board of Directors. Change in board composition is the result of a strategic refocus for the FRA, and those recently appointed to the board include: Donald M. Elliman, Jr.; William Freytag, PhD; James C. T. Linfield; and David Perez.
Similar a Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in the Bioscience Industry to Its Board of Directors
Similar a Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in the Bioscience Industry to Its Board of Directors (20)
Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in the Bioscience Industry to Its Board of Directors
1. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of
Four Key Leaders in the Bioscience Industry to Its Board of Directors
The Fitzsimons Redevelopment Authority (FRA) is adding four of the area's most well‐known and successful
leaders in the Bioscience Industry to its Board of Directors. Change in board composition is the result of a
strategic refocus for the FRA, and those recently appointed to the board include: Donald M. Elliman, Jr.;
William Freytag, PhD; James C. T. Linfield; and David Perez.
Aurora, CO, November 15, 2011 ‐ In a strategic effort to refocus and strengthen its organization, the
Fitzsimons Redevelopment Authority (FRA) has completed a regimen of planning to make adjustments in the
direction, roles, responsibilities and allocation of resources going forward. The announcement is made by
Denise Brown, FRA Interim Executive Director, who says, "Our first tactic in refocus involves augmenting our
board of directors with four of the area's most well‐known and successful leaders in the bioscience industry to
help build programs and services to attract bioscience companies to relocate to Colorado and keep growing
Colorado‐based bioscience companies here, adding to our employment base. The action to modify the board
accordingly was approved in a recent board action."
Joining the FRA Board are Donald M. Elliman, Jr., Executive Director of the Charles C. Gates Center for
Regenerative Medicine and Stem Cell Biology and current Director and former Chair of the Children's Hospital
Colorado Board of Directors; William Freytag, PhD, former Chairman and CEO of Myogen, Inc.; James C. T.
Linfield, Partner‐in‐Charge of the Colorado office of Cooley LLP; and David Perez, President and Chief
Executive Officer of CaridianBCT, becoming TerumoBCT.
Brown continues, "We're very pleased to welcome our new board members. These leaders are actively
involved the bioscience community ‐ locally, nationally and internationally ‐ and maintain those critical
relationships with entrepreneurs, companies and research groups required to guide the FRA through its next
phase of growth. This is the first time the FRA has had bioscience executives on its board."
As background, in 1996, the City of Aurora and University of Colorado worked together to create a special‐
purpose governmental entity, giving it a single mission: to imagine and govern the evolution of a historic army
medical center into one of the world’s most forward‐looking bioscience districts. In partnership with the
University of Colorado and the City of Aurora, the FRA acquired much of the former army site and began to
implement an ambitious redevelopment plan that now comprises the growing and thriving Fitzsimons Life
Science District that includes the Colorado Science + Technology Park now adjacent to the Anschutz Medical
Campus and the new V.A. hospital campus.
"As the Fitzsimons site has matured, it's become clear to the FRA board that it needed to do more to support
the growth of early‐stage Colorado bioscience companies, especially those developing technologies from
Colorado's research institutions, with an emphasis on those technologies developed at the Anschutz Medical
Campus. Hence, the FRA is now addressing the critical need to bring bioscience‐focused leadership to the
board process in building new corporate partnerships and leveraging the strength of the Anschutz Medical
Campus and the FRA's real estate development partner, the Forest City Science + Technology Group," Brown
explains.
‐More‐